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Abstract: Heparin coating modifies complement activa- 
tion during extracorporeal circulation much more effcc- 
lively than systemically administered heparin. This rabbit 
study was undertaken to address possible mechanisms 
responsible for this difference. We evaluated the effect of 
heparin coating on complement activation and subse- 
quently the release of leukocyte inflammatory mediators 
during extracorporeal circulation through a simplified cir- 
cuit. We found in the heparin-coated group a significantly 
reduced complement hemolytic activity (CH5,)), remaining 
higher leukocyte numbers, significantly decreased release 
of P-glucuronidase, and most strikingly a complete pre- 
vention of tumor necrosis factor (TNF) formation. 'The 
significantly reduced CHo, activity in the heparin-coated 
groups indicates the reduction of one or more native classi- 
cal complement products. This could be explained by the 
absorption of complement components by the circuit, 
which results in reduced activity of the complement cas- 
cade. We conclude therefore that heparin coating reduces 
complement activation and consequently reduces the re- 
lease of leukocyte inflammatory mediators. Key Words: 
Complement-Leukocytes-Tumor necrosis factor- 
Extracorporeal circulation-Heparin coating-Biocom- 
patibility. 
Cardiopulmonary bypass (CPB) is associated with 
complement activation of both classical and alterna- 
tive pathways (1-6). Both pathways form C3-con- 
vertase, an enzyme able to cleave C3 and thus gener- 
ate C3a and C3b. The formation of the C3- 
convertase is a critical step in activation of the com- 
plement cascade since it augments initial C3 cleav- 
age and will recruit the effector sequence composed 
of complement products CS to C9, which will gener- 
ate the vasoactive, chemotactic, immune regulatory, 
and cytolytic activity of complement (7,s). 
Heparin is known to inhibit the complement sys- 
tem by interfering with C3-convertase formation in 
either the classical or alternative pathway in concen- 
trations similar to those needed for anticoagulation 
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(9-1 1) .  However, despite heparinization comple- 
ment activation through both pathways has still been 
demonstrated in patients undergoing CPB, probably 
owing to interaction of heparin with other plasma 
proteins. On the other hand, several studies reported 
the inhibitory effect of heparin coating on comple- 
ment activation (12-14). This observation indicate5 
that the inhibitory action of heparin on complement 
activation is much more effective by coating the 
total inner surface of the extracorporeal circuit with 
heparin. 
However, it remains unclear why heparin coating 
is much more effective than systemically adminis- 
tered heparin in modifying complement activation. 
We hypothesize that heparin coating may promote 
the absorption of native complement products by 
the extracorporeal circuit, thus preventing the gen- 
eration of complement split products. This rabbit 
study was undertaken to evaluate the effect of hepa- 
rin coating on complement activation and subsc- 
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quently the release of leukocyte inflammatory medi- 
ators during extracorporeal circulation through a 
simplified circuit. 
MATERIALS AND METHODS 
Animals 
Fasted New Zealand white rabbits were anesthe- 
tized with intramuscular injections of xylazine (20 
mg/kg) and ketamine (25 mg/kg). Additional anes- 
thesia was maintained with ketamine. The rabbits 
were secured in a supine position and prepared for 
surgery. A tracheostomy was performed, and a 
cuffless endotracheal tube was fitted, secured with 
a proximal suture to prevent leakage. The rabbits 
were ventilated with room air at a respiratory rate 
appropriate to maintain normal end-tidal capnogra- 
phy with a positive-end expiratory pressure (PEEP) 
of 2 cm H20 .  The positive inspiratory pressure (PIP) 
was maintained between 20 and 30 cm HzO per aus- 
cultation, the pH was kept over 7.40, and the Pco, 
less than 40 mm Hg, to ensure the absence of sponta- 
neou5 ventilatory efforts. The left carotid artery was 
cannulated to provide a site for sampling blood and 
blood pressure measurements. The left and the right 
internal jugular veins were surgically isolated and 
served as the cannulation sites for venovenous 
bypass. 
Extracorporeal circuit 
The bypass circuit consisted of 1 m of one- 
quarter-inch by one-sixteenth-inch flexible poly- 
vinylchloride (PVC) tubing, argyle PVC catheters 
(No. 8 )  for vascular access, and three-sixteenth-inch 
by one-quarter-inch rigid PVC connectors. In some 
of the study groups, tubing, catheters, and connec- 
tors were heparin coated (Carmeda, Medtronic 
Blood Systems, Anaheim, CA, U.S.A.). The circuit 
was primed with Ringer’s lactate and inserted in a 
roller pump with occlusion settings according to the 
clinical protocol of neonatal extracorporeal life sup- 
port. The jugular veins were cannulated and con- 
nected to the tubing. The total circuit volume was 
approximately 30 ml. Bypass was maintained at a 
flow rate of approximately 60-80 ml/min (or 20 
ml/kg) for 2 h. Thereafter, the animal was sacrificed 
with an overdose of xylazine followed by potassium 
chloride. Death was verified by cardiac monitoring. 
Experimental groups 
Four experimental groups were studied: Group 
A (n = 5 )  being an uncoated circuit and systemic 
heparinization, Group B (n = 5) being an uncoated 
circuit without systemic heparinization, Group C 
(n = 5 )  a heparin-coated circuit plus systemic hepa- 
rinization, and Group D (n = 5 )  a heparin-coated 
circuit but without systemic heparinization. Animals 
with baseline hematologic abnormalities or those 
that developed technical complications were ex- 
cluded from this study. 
Blood collection 
Blood samples were drawn immediately after the 
insertion of the arterial catheter (baseline) and 10, 
30, 60, and 120 min after the onset of bypass. The 
amount of blood drawn at each time point was 3 ml. 
One milliliter of blood, anticoagulated with ethylene- 
diarninetetraacetic acid (EDTA, 0.01 M ) ,  was col- 
lected for blood cell counts. Two milliliters of blood 
was anticoagulated with 0.3% sodium citrate and 
centrifuged, and the plasma was stored at - 80°C for 
complement (CH,,,) assays and for determination of 
p-glucuronidase and tumor necrosis factor (TNF). 
Assays 
Leukocyte numbers were counted with a cell 
counter (Counter Electronics, Inc., Hialeah, FL,  
U.S.A.). Hemoglobin was measured using a IL 482 
co-oximeter (Instrumentation Laboratories, Lexing- 
ton, MA, U.S.A.). The complement hemolytic assay 
(CH,,,) was performed according to Mayer (IS) with 
sheep red blood cells incubated with I : 2 to I : 32 
stepwise diluted rabbit serum. The p-glucuronidase 
plasma concentration was measured according to 
Baehner (16). A mixture of 1 ml substrate p-ni- 
trophenyl p-D-glucopyranosid uric acid solution 
(Merck, Darmstadt, Germany) and 50 pl rabbit 
plasma was incubated for 2 h at room temperature. 
The conversion of the substrate by plasma p-gluc- 
uronidase was determined in a spectrophotometer 
at 410 nm. TNF activity in the plasma was measured 
using a sensitive bioassay with the WEHI 164 sub- 
clone 13 cell line as previously described (17). 
Statistics 
The data of leukocyte numbers, CHjo, p-gluc- 
uronidase, and T N F  concentrations were corrected 
for dilution and are presented as means k standard 
deviation (SD) for each group. One-way analysis of 
variance (ANOVA) was used to assess differences 
of means between groups. A p value of less than 
0.05 was considered to be significant. 
RESULTS 
Complement consumption (CH,,) 
In the uncoated group the CH50 remained un- 
changed throughout the entire period of extracorpo- 
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FIG. 1. Complement hemolytic activity (CH,,) expressed as 
mean percentage of initial value in the control group (open 
circle), in the uncoated without systemic heparin group 
(closed circle), in the heparin-coated group with systemic 
heparin (open square), and in that without systemic heparin 
(closed square). 'p < 0.05 vs. Group A; "p < 0.05 vs. Group 
A and vs. Group B. 
real circulation (Fig. I ) .  In the heparin-coated 
groups, however, the CHso decreased immediately 
after start of bypass, and a level of about 70% of 
baseline was reached after 1 h (p < 0.05). This level 
was maintained during the rest of the bypass. 
Leukocyte numbers 
The leukocyte numbers dropped immediately 
after the start of extracorporeal circulation in all 
groups (Fig. 2). Minimum levels were reached 30 
l o o  
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FIG. 2. Leukocyte numbers expressed as mean percentage of 
initial value in the control group (open circle), in the uncoated 
without systemic heparin group (closed circle), in  the heparin- 
coated group with systemic heparin (open square), and in 
that without systemic heparin (closed square). 'p < 0.05 vs. 
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FIG. 3. P-Glucuronidase concentrations expressed as means 
in the control group (open circle), in  the uncoated without 
systemic heparin group (closed circle), in  the heparin-coated 
group with systemic heparin (open square), and in that with- 
out systemic heparin (closed square). 'p < 0.05 vs. Group A. 
min after the start of bypass and were respectively 
50% of initial value in the noncoated groups and 
70% in the heparin-coated groups. The leukocyte 
numbers remained significantly higher in the hepa- 
rin-coated groups throughout the entire period of 
bypass than in the noncoated groups (p < 0.05). 
Leukopenia was still present in all groups after 2 h 
of extracorporeal circulation. 
P-Glucuronidase 
The granulocytic release product p-glucuronidase 
increased rapidly upon start of bypass in all groups 
but was significantly lower in the heparin-coa.ted 
groups (p < 0.05) (Fig. 3). After 2 h of bypass, the 
P-glucuronidase concentrations increased in the un- 
coated groups with systemic heparin to 2,029 ? 902 
IU and without systemic heparin to 1,796 5 1,043 
IU. At that time point, the P-glucuronidase concen- 
trations increased in the heparin-coated groups with 
systemic heparin to 1,140 * 420 IU and without 
systemic heparin to 1,380 k 656 IU. These increases 
and differences between the groups correlated in- 
versely with the decrease in leukocyte numbers. 
Tumor necrosis factor 
TNF concentrations increased rapidly upon start 
of bypass in the uncoated groups to about 300% of 
initial value after 30 min of bypass (Fig. 4). In the 
heparin-coated group, no increase in T N F  was mea- 
sured throughout the entire period of bypass, thus 
TNF was significantly lower in the heparin-coated 
groups (p < 0.05). After 2 h of extracorporeal circu- 
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FIG. 4. TNF concentrations expressed as mean percentage of 
initial value in the control group (open circle), in the uncoated 
without systemic heparin group (closed circle), in the heparin- 
coated group with systemic heparin (open square), and in 
that without systemic heparin (closed square). 'p < 0.05 vs. 
Group A. 
lation, TNF was still elevated in the uncoated 
groups. 
DISCUSSION 
Complement activation during extracorporeal cir- 
culation is modified by coating the blood-contact 
surfaces with endpoint-attached, functionally active 
heparin. This is substantiated by the significantly 
reduced CHso activity, the remaining higher leuko- 
cyte numbers, the significantly decreased release of 
P-glucuronidase, and most strikingly the complete 
prevention of TNF formation in the heparin-coated 
group. 
The significantly reduced CH,, activity in the hep- 
arin-coated groups indicates the inhibitory action of 
heparin coating on complement activation. The CH,, 
assay represents the ability of plasma to generate the 
terminal complement complex through the classical 
pathway, which has cell-membrane-attacking capac- 
ity. Red blood cells (RBC) present in the assay are 
targets for the activated complement proteins and 
will be lysed in the assay only if all the complement 
proteins are present in adequate levels and are func- 
tional. The complement protein present in the lowest 
concentration (i.e., the minimum concentration re- 
quired for further activation) is the limiting factor in 
the amount of lysis a test serum will produce. 
The significantly reduced CH,, activity in the 
plasma samples obtained from the heparin-coated 
groups indicates the reduction of one or more native 
classical complement products. This reduction may 
be due to high activation and subsequent consump- 
tion during extracorporeal circulation of rabbit 
blood. Alternatively, the reduction may be due to 
loss of complement components during extracorpo- 
real circulation without activation. An enhanced ac- 
tivation process by heparin coating is not likely since 
heparin has been shown to inhibit C3-convertase 
(9- 11) .  Thus, heparin coating may promote the bind- 
ing of certain complement factors to the surface of 
the heparin-coated extracorporeal circuit and subse- 
quently cause depletion of these factors in the fluid 
phase. The complement cascade will then exert re- 
duced activity ex vivo. The hypothesis that comple- 
ment factors bind to the heparin-coated surface may 
also explain the difference between the effects of 
systemic heparin and heparin coating even when the 
affinities between complement factors and heparin 
are similar. Once bound to systemic heparin, the 
complement factors remain in circulation and obvi- 
ously can still be recruited to allow the cascade to 
function normally. However, we realize that the sup- 
port for our hypothesis is not complete. We were 
unable to measure in this rabbit model the absorption 
of complement components to the surface or to mea- 
sure quantitative levels of individual components in 
plasma; therefore, it is necessary to perform further 
studies to elucidate which complement components 
are truly absorbed. 
Although we were unable to measure quantitative 
levels of complement products in our in vivo rabbit 
model, it is likely that only small amounts of the 
bioactive complement products C5a and C5b-9 were 
formed in the heparin-coated groups. This assump- 
tion is supported both by ex vivo studies with human 
blood and by in vivo studies in which no or only 
small amounts of C5a were formed in heparin-coated 
circuits (13,14). Furthermore, C5a stimulates mono- 
cytes to release TNF ( I @ ,  which was completely 
prevented in the heparin-coated groups. However, 
the possibility may exist that TNF is produced as 
well in the heparin-coated groups but that TNF is 
also absorbed by the circuit. 
The inhibitory effect of heparin coating on C5a 
generation is also in accordance with the positive 
effect on leukocyte numbers and the lower concen- 
trations of P-glucuronidase. C5a stimulates leuko- 
cytes to adhere, to aggregate on endothelial cells, to 
migrate extravascularly, and to release their en- 
zymes (19-21). Aggregation of polymorphonuclear 
leukocytes (PMN) results in leukopenia and their 
pulmonary sequestration (22,23). The activation of 
leukocytes is reflected by the elevated concentra- 
tions of release products, such as elastase or P-gluc- 
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uronidase (24,25). These inflammatory mediators 
are considered to be responsible for the whole-body 
inflammatory reaction in CPB, causing organ dys- 
function (1-6); thus heparin coating may be of great 
clinical importance in reducing this reaction during 
extracorporeal life support. 
In conclusion, this study showed that heparin 
coating improved the biocompatibility of extracor- 
poreal circuits by modifying complement activation 
in such a way that it reduced the release of leukocyte 
inflammatory mediators during extracorporeal cir- 
culation. 
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